基于MRI影像组学在乳腺癌分子分型的研究进展

doi:10.3969/j.issn.1674-490X.2024.02.004

摘要/Abstract

摘要： 乳腺癌严重影响女性身心健康,是女性最常见的恶性肿瘤,其依据病理不同进行分子分型,早期识别病理分型和靶向治疗是改善患者预后的关键。病理虽为金标准也存在一定不足,如操作的有创性、标本取材的局限性以及检测时间要求的限制性。影像组学通过深度挖掘影像图像多维度特征,将肿瘤的异质性进行量化处理,采用一种无创性、简便的方法对肿瘤的生物学特性进行综合评价,在乳腺癌分子分型的发现、预测淋巴结转移、制订治疗方案、评估治疗效果、判断患者预后等方面已得到广泛应用。现拟基于MRI影像组学特征对乳腺癌分子分型的应用现状进行综述。

关键词: 乳腺癌, 分子分型, 影像组学, 磁共振成像

Abstract: Breast cancer is the most common malignant tumor in women, which seriously affects the physical and mental health of women. Molecular classification according to pathology, early identification of pathological classification and targeted therapy play a decisive role in ameliorating prognosis of patients. Although pathology is the gold standard, there are some shortcomings, such as the invasiveness of operation, the limitation of sampling and the limitation of testing time. By deeply mining the multi-dimensional features of the image, radiomics quantifies the heterogeneity of the tumor, and uses a non-invasive and simple method to comprehensively evaluate the biological characteristics of the tumor, it has been widely used in the discovery of molecular classification of breast cancer, prediction of LNM, formulation of treatment plan, evaluation of treatment effect, prognosis of patients and so on. In this paper, the application of molecular typing of breast cancer based on MRI radiomics -本文引用:李昊,侯岩,殷小平.基于MRI影像组学在乳腺癌分子分型的研究进展［J］.医学研究与教育,2024,41(2):21-28.DOI:10.3969/j.issn.1674-490X.2024.02.004.·临床医学·基于MRI影像组学在乳腺癌分子分型的研究进展李昊^1,2,侯岩¹,殷小平^1,3(1.河北大学附属医院放射科,河北保定 071000;2.河北省保定市第一中心医院超声一科,河北保定 071000;3.河北省炎症相关肿瘤精确影像学重点实验室,河北保定 071000)摘要:乳腺癌严重影响女性身心健康,是女性最常见的恶性肿瘤,其依据病理不同进行分子分型,早期识别病理分型和靶向治疗是改善患者预后的关键。病理虽为金标准也存在一定不足,如操作的有创性、标本取材的局限性以及检测时间要求的限制性。影像组学通过深度挖掘影像图像多维度特征,将肿瘤的异质性进行量化处理,采用一种无创性、简便的方法对肿瘤的生物学特性进行综合评价,在乳腺癌分子分型的发现、预测淋巴结转移、制订治疗方案、评估治疗效果、判断患者预后等方面已得到广泛应用。现拟基于MRI影像组学特征对乳腺癌分子分型的应用现状进行综述。关键词:乳腺癌;分子分型;影像组学;磁共振成像DOI:10.3969/j.issn.1674-490X.2024.02.004中图分类号:R44 文献标志码:A 文章编号:1674-490X(2024)02-0021-08Advances on MRI radiomics in molecular typing of breast cancerLI Hao^1,2, HOU Yan¹, YIN Xiaoping^1,3(1. Department of Radiology, Affiliated Hospital of Hebei University, Baoding 071000, China; 2. NO.1 Department of Ultrasound, Baoding NO.1 Central Hospital, Baoding 071000, China; 3. Hebei Key Laboratory of Precise Imaging of Inflammation Related Tumors, Baoding 071000, China)Abstract: Breast cancer is the most common malignant tumor in women, which seriously affects the physical and mental health of women. Molecular classification according to pathology, early identification of pathological classification and targeted therapy play a decisive role in ameliorating prognosis of patients. Although pathology is the gold standard, there are some shortcomings, such as the invasiveness of operation, the limitation of sampling and the limitation of testing time. By deeply mining the multi-dimensional features of the image, radiomics quantifies the heterogeneity of the tumor, and uses a non-invasive and simple method to comprehensively evaluate the biological characteristics of the tumor, it has been widely used in the discovery of molecular classification of breast cancer, prediction of LNM, formulation of treatment plan, evaluation of treatment effect, prognosis of patients and so on. In this paper, the application of molecular typing of breast cancer based on MRI radiomics -收稿日期:2023-05-13基金项目:河北省高层次人才资助项目(B20231008)第一作者:李昊(1989—),女,河北保定人,主治医师,硕士,主要从事乳腺影像学诊断。E-mail: vickyhbbd77@126.com通信作者:殷小平(1978—),女,河北保定人,主任医师,博士,博士生导师,主要从事人工智能应用及腹部肿瘤影像学诊断。E-mail: yinxiaoping78@sina.com第2期李昊等:基于MRI影像组学在乳腺癌分子分型的研究进展2024年characteristics is reviewed.

Key words: breast cancer, molecular typing, radiomics, magnetic resonance imaging

中图分类号:

李昊, 侯岩, 殷小平. 基于MRI影像组学在乳腺癌分子分型的研究进展[J]. 医学研究与教育, 2024, 41(2): 21-28.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2] ZHENG R S, ZHANG S W, ZENG H M, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9. DOI: 10.1016/j.jncc.2022.02.002.
[3] BRITT K L, CUZICK J, PHILLIPS K A. Key steps for effective breast cancer prevention[J]. Nat Rev Cancer, 2020, 20(8): 417-436. DOI: 10.1038/s41568-020-0266-x.
[4] SUN Y S, ZHAO Z, YANG Z N, et al. Risk factors and preventions of breast cancer[J]. Int J Biol Sci, 2017, 13(11): 1387-1397. DOI: 10.7150/ijbs.21635.
[5] GILLIES R J, ANDERSON A R, GATENBY R A, et al. The biology underlying molecular imaging in oncology: from genome to anatome and back again[J]. Clin Radiol, 2010, 65(7): 517-521. DOI: 10.1016/j.crad.2010.04.005.
[6] LIU Z Y, WANG S, DONG D, et al. The applications of radiomics in precision diagnosis and treatment of oncology: opportunities and challenges[J]. Theranostics, 2019, 9(5): 1303-1322. DOI: 10.7150/thno.30309.
[7] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J].中国癌症杂志, 2021, 31(10): 954-1040. DOI: 10.19401/j.cnki.1007-3639.2021.10.013.
[8] LI H, SUN H, LIU S Q, et al. Assessing the performance of benign and malignant breast lesion classification with bilateral TIC differentiation and other effective features in DCE-MRI[J]. J Magn Reson Imaging, 2019, 50(2): 465-473. DOI: 10.1002/jmri.26646.
[9] JIANG Y L, EDWARDS A V, NEWSTEAD G M. Artificial intelligence applied to breast MRI for improved diagnosis[J]. Radiology, 2021, 298(1): 38-46. DOI: 10.1148/radiol.2020200292.
[10] MARTELOTTO L G, NG C K Y, PISCUOGLIO S, et al. Breast cancer intra-tumor heterogeneity[J]. Breast Cancer Res, 2014, 16(3): 210. DOI: 10.1186/bcr3658.
[11] PEROU C M, SØRLIE T, EISEN M B, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797): 747-752. DOI: 10.1038/35021093.
[12] GOLDHIRSCH A, WOOD W C, COATES A S, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol, 2011, 22(8): 1736-1747. DOI: 10.1093/annonc/mdr304.
[13] 刘月平,步宏,杨文涛. 2019版中国乳腺癌HER2检测指南更新解读[J].中华病理学杂志, 2019, 48(3): 182-185. DOI: 10.3760/cma.j.issn.0529-5807.2019.03.004.
[14] CASTALDO R, PANE K, NICOLAI E, et al. The impact of normalization approaches to automatically detect radiogenomic phenotypes characterizing breast cancer receptors status[J]. Cancers, 2020, 12(2): 518. DOI: 10.3390/cancers12020518.
[15] LEITHNER D, BERNARD-DAVILA B, MARTINEZ D F, et al. Radiomic signatures derived from diffusion-weighted imaging for the assessment of breast cancer receptor status and molecular subtypes[J]. Mol Imaging Biol, 2020, 22(2): 453-461. DOI: 10.1007/s11307-019-01383-w.
[16] WANG Q L, MAO N, LIU M J, et al. Radiomic analysis on magnetic resonance diffusion weighted image in distinguishing triple-negative breast cancer from other subtypes: a feasibility study[J]. Clin Imaging, 2021, 72: 136-141. DOI: 10.1016/j.clinimag.2020.11.024.
[17] FAN M, ZHANG P, WANG Y, et al. Radiomic analysis of imaging heterogeneity in tumours and the surrounding parenchyma based on unsupervised decomposition of DCE-MRI for predicting molecular subtypes of breast cancer[J]. Eur Radiol, 2019, 29(8): 4456-4467. DOI: 10.1007/s00330-018-5891-3.
[18] 陆欢,葛敏,王世威.动态增强MRI瘤内与瘤周影像组学特征对三阴性乳腺癌的诊断价值研究[J].浙江医学, 2021, 43(15): 1647-1651, 1710. DOI: 10.12056/j.issn.1006-2785.2021.43.15.2020-2722.
[19] XIE T W, ZHAO Q F, FU C X, et al. Differentiation of triple-negative breast cancer from other subtypes through whole-tumor histogram analysis on multiparametric MR imaging[J]. Eur Radiol, 2019, 29(5): 2535-2544. DOI: 10.1007/s00330-018-5804-5.
[20] LI C L, SONG L R, YIN J D. Intratumoral and peritumoral radiomics based on functional parametric maps from breast DCE-MRI for prediction of HER-2 and ki-67 status[J]. J Magn Reson Imaging, 2021, 54(3): 703-714. DOI: 10.1002/jmri.27651.
[21] BRAMAN N, PRASANNA P, WHITNEY J, et al. Association of peritumoral radiomics with tumor biology and pathologic response to preoperative targeted therapy for HER2(ERBB2)-positive breast cancer[J]. JAMA Netw Open, 2019, 2(4): e192561. DOI: 10.1001/jamanetworkopen.2019.2561.
[22] DILORENZO G, TELEGRAFO M, FORGIA D L, et al. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type[J]. Eur J Radiol, 2019, 113: 148-152. DOI: 10.1016/j.ejrad.2019.02.018.
[23] THOMPSON C M, MALLAWAARACHCHI I, DWIVEDI D K, et al. The association of background parenchymal enhancement at breast MRI with breast cancer: a systematic review and meta-analysis[J]. Radiology, 2019, 292(3): 552-561. DOI: 10.1148/radiol.2019182441.
[24] 张东蕾,钱银锋,李伟,等.影响乳腺癌腋窝淋巴结转移的因素分析及不同诊断方式的对比研究[J].中国临床医学影像杂志, 2021, 32(2): 94-99. DOI: 10.12117/jccmi.2021.02.005.
[25] 王季,张意辉,张丽娟,等.体重指数及体重波动对乳腺癌患者上肢淋巴水肿的影响[J].中国康复医学杂志, 2020, 35(2): 182-185. DOI: 10.3969/j.issn.1001-1242.2020.02.011.
[26] GUPTA S, GUPTA N, KADAYAPRATH G, et al. Use of sentinel lymph node biopsy and early physiotherapy to reduce incidence of lymphedema after breast cancer surgery: an institutional experience[J]. Indian J Surg Oncol, 2020, 11(1): 15-18. DOI: 10.1007/s13193-019-01030-4.
[27] 罗焱文,朱庆莉.乳腺癌影像组学研究进展[J].协和医学杂志, 2021, 12(6): 983-988. DOI: 10.12290/xhyxzz.2021-0011.
[28] 邢滔,陈基明,颜秀芳,等.MRI纹理分析预测乳腺癌腋窝淋巴结转移的价值[J].临床放射学杂志, 2019, 38(12): 2290-2294. DOI: 10.13437/j.cnki.jcr.2019.12.015.
[29] 夏旭东,段成洲,王功夏,等.MRI纹理分析预测乳腺癌腋窝淋巴结转移[J]. 中国医学影像技术, 2021, 37(4): 531-536. DOI: 10.13929/j.issn.1003-3289.2021.04.013.
[30] YU Y F, TAN Y J, XIE C M, et al. Development and validation of a preoperative magnetic resonance imaging radiomics-based signature to predict axillary lymph node metastasis and disease-free survival in patients with early-stage breast cancer[J]. JAMA Netw Open, 2020, 3(12): e2028086. DOI: 10.1001/jamanetworkopen.2020.28086.
[31] TANG Y Q, CHEN L, QIAO Y T, et al. Radiomic signature based on dynamic contrast-enhanced MRI for evaluation of axillary lymph node metastasis in breast cancer[J]. Comput Math Methods Med, 2022, 2022: 1507125. DOI: 10.1155/2022/1507125.
[32] KAMANGAR F, DORES G M, ANDERSON W F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world[J]. J Clin Oncol, 2006, 24(14): 2137-2150. DOI: 10.1200/JCO.2005.05.2308.
[33] KORDE L A, SOMERFIELD M R, CAREY L A, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline[J]. J Clin Oncol, 2021, 39(13): 1485-1505. DOI: 10.1200/JCO.20.03399.
[34] TESHOME M, HUNT K K. Neoadjuvant therapy in the treatment of breast cancer[J]. Surg Oncol Clin N Am, 2014, 23(3): 505-523. DOI: 10.1016/j.soc.2014.03.006.
[35] 刘宏,张凤翔,张芳.DCE-MRI半定量及定量分析在鉴别颈部淋巴结良恶性中的研究现状[J].磁共振成像, 2021, 12(1): 103-105. DOI: 10.12015/issn.1674-8034.2021.01.024.
[36] LIU J, SUN D, CHEN L L, et al. Radiomics analysis of dynamic contrast-enhanced magnetic resonance imaging for the prediction of sentinel lymph node metastasis in breast cancer[J]. Front Oncol, 2019, 9: 980. DOI: 10.3389/fonc.2019.00980.
[37] CABALLO M, SANDERINK W B G, HAN L Y, et al. Four-dimensional machine learning radiomics for the pretreatment assessment of breast cancer pathologic complete response to neoadjuvant chemotherapy in dynamic contrast-enhanced MRI[J]. J Magn Reson Imaging, 2023, 57(1): 97-110. DOI: 10.1002/jmri.28273.
[38] PARK H, LIM Y, KO E S, et al. Radiomics signature on magnetic resonance imaging: association with disease-free survival in patients with invasive breast cancer[J]. Clin Cancer Res, 2018, 24(19): 4705-4714. DOI: 10.1158/1078-0432.CCR-17-3783.